Correction to: Rudolf A de Boer, Johann Bauersachs, The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies, European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 342–344, https://doi.org/10.1093/eurheartj/ehac781
The following acknowledgements were omitted from the legend of the graphical abstract as first published:
Panel A. Primary endpoint of DELIVER [cardiovascular (CV) death or heart failure (HF) hospitalization] in the entire population (left) and in the population with LVEF <60%. Reprinted with permission from Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced and preserved ejection fraction. N Engl J Med 2022;387:1089–1098. https://doi.org/10.1056/NEJMoa2206286
Panel B. A pooled analysis of patients enrolled in the DAPA-HF and DELIVER trials reveals a consistent benefit of dapagliflozin on the primary endpoint (CV death or HF hospitalization) across the entire spectrum of LVEF, with no signs of attenuation of the effect in the higher LVEF range. Reprinted with permission from Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin and outcomes across the range of ejection fraction in patients with heart failure: a pooled analysis of DAPA-HF and DELIVER. Lancet 2022;28:1956–1964. https://doi.org/10.1038/s41591-022-01971-4
Panel C. Effect of acetazolamide on congestion in the ADVOR trial. From Day 1 onwards, the use of acetazolamide on top of regular loop diuretics resulted in accelerated decongestion. Reprinted with permission from Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 2022;387:1185–1195. https://doi.org/10.1056/NEJMoa2203094
Panel D. Kaplan–Meier estimates of all-cause mortality or HF hospitalization for patients receiving PCI or optimal medical therapy in the REVIVED trial. LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention. Reprinted with permission from Perera D, Clayton T, O’Kane PD, Greenwood JP, Weerackody R, Ryan M, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med 2022;387:1351–1360. https://doi.org/10.1056/NEJMoa2206606
This missing acknowledgments have been added to the legend of the graphical abstract, and the paper has now been corrected online.